Biotech News

argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities

Argenx (ARGX)ArgenxCompany update

Amsterdam, the Netherlands, November 9, 2026, 07:00 CET – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced a definitive agreement to acquire Unnatural Products, Inc. (UNP), adding a macrocyclic peptide discovery engine to its immunology innovation capabilities. argenx, which already holds a minority stake in UNP, will acquire all remaining shares in a transaction valuing UNP at up to approximately $1.15 billion across upfront and milestone payments. This acquisition expands the ways argenx can pursue novel biology and develop oral or long-acting medicines for people living with serious immune-mediated diseases.

Related news

Argenx

Global Immunology Company Argenx develops therapies for severe autoimmune diseases. Its core commercial asset, VYVGART/efgartigimod, targets FcRn to reduce circulating IgG autoantibodies and has established a commercial base in generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and selected regional...

Recent company news

Stock data

Close
942.04 USD
Market cap
49.89B USD
Exchange
NASDAQ
Sector
Antibody Drugs
Location
United States